Pieris Pharmaceuticals, Inc. (PIRS)

Superior Medicines Through Efficient Biology

We combine leading protein engineering capabilities and deep insights into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes.

Our Anticalin^® Platform

Our Pursuit of Efficient Biology in Two Areas

Novel Solutions in Respiratory & Immuno-Oncology

Our pipeline is focused on inhalable Anticalin proteins to treat respiratory diseases locally and immuno-oncology multi-specifics tailored for the tumor microenvironment.

Browse Our Pipeline

We Are Biology-driven, Patient-focused

Actively Enrolling Patients in Clinical Trials

In our quest to provide solutions for patients, we are currently enrolling for our respiratory and immuno-oncology clinical trials.

View Our Patient Resources

Latest News

View All News

May 25, 2021

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech

View Press Release

May 20, 2021

Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

View Press Release

May 17, 2021

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

View Press Release

View All News

Join us in our mission to develop life-changing therapies!

Our passion and enthusiasm for science seek to transform the lives of patients. Learn more about how you can join our exceptional team!

Browse Career Opportunities